RenFuel and Nordic Paper have signed an agreement to build a production test facility in Bäckhammar in the region of Värmland, Sweden in order to test-manufacture an advanced biofuel based on lignin. The project has been granted 71 million SEK by the Swedish Energy Agency. The Swedish bioenergy research firm RenFuel has developed and patented a method to refine the lignin from black liquor, a renewable byproduct from the production of paper pulp, into lignin oil. The oil, called Lignol, can replace fossil oil and be used as raw material in the production of renewable gasoline and diesel. Using the black liquor also leads to an increase in production capacity and profit in the paper pulp industry. “Our product Lignol is the key to reaching the goal of a fossil free vehicle fleet in Sweden by 2030. We are very pleased to finally being able to put the product into large scale testing, as a result of the cooperation with Nordic Paper and the financial support from the Swedish Energy Agency,” Sven Löchen, CEO of RenFuel said.
Two Sides North America is pleased to welcome the Pharmaceutical Printed Literature Association (PPLA) as its newest member. PPLA is a coalition representing printers, equipment manufacturers, raw material suppliers and distributors of regulated printed pharmaceutical information used by both medical professionals and patients, including package inserts, medication guides, and other label packaging such as folding cartons and pressure-sensitive labels. PPLA’s 25 member companies employ thousands of individuals across manufacturing operations in 15 states.
“As Two Sides continues to grow our membership across all sectors of the print, paper and paper-based packaging industry, we are delighted to have PPLA join us and look forward to working with them to help promote the sustainability of our industry and our products, and printed pharmaceutical information in particular,” said Two Sides North America President Kathi Rowzie.
Chartered in 2001, PPLA is the leader in advancing patient safety through the use of printed medical information. PPLA has long advocated for federal and regulatory policies to uphold the continued and broad utilization of printed pharmaceutical literature, including patient medication information and package inserts for professional use. PPLA is committed to supporting provider preference and empowering patients by ensuring medication information is accessible in a reliable, printed format.
“Printed medication information is critical for patients, caregivers, and health care providers to understand prescription drug dosage, administration, side effects, adverse reactions and interactions with other drugs,” says PPLA Chairman Dave Joesten. “Two Sides does a great job of telling the sustainability story of paper communication, and we are excited to work with them to amplify PPLA’s message that printed medication information is not only essential, but also environmentally responsible.”